NASDAQ:IMUX Immunic (IMUX) Stock Price, News & Analysis $6.66 -0.23 (-3.34%) Closing price 04:00 PM EasternExtended Trading$6.53 -0.13 (-1.95%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Immunic Stock (NASDAQ:IMUX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immunic alerts:Sign Up Key Stats Today's Range$6.35▼$7.0450-Day Range$6.66▼$16.9052-Week Range$5.06▼$17.43Volume438,037 shsAverage Volume300,193 shsMarket Capitalization$90.84 millionP/E RatioN/ADividend YieldN/APrice Target$35.43Consensus RatingBuy Company Overview Immunic, Inc. is a clinical-stage biotechnology company developing orally administered therapies for chronic inflammatory and autoimmune diseases. The company focuses on selectively modulating the immune system while seeking to avoid broad immunosuppression, with an emphasis on conditions affecting the central nervous system and gastrointestinal tract. Immunic’s lead investigational product is vidofludimus calcium, formerly known as IMU-838. The oral, selective dihydroorotate dehydrogenase inhibitor is being studied in clinical trials for multiple sclerosis, including relapsing and progressive forms of the disease. Immunic is also advancing earlier-stage programs such as IMU-856, which targets Sirtuin 6 and is being evaluated for intestinal disorders, and IMU-381, an investigational molecule intended for immune-mediated diseases. Immunic was established in 2016 and became a publicly traded company in 2019 through a merger with Vital Therapies, subsequently adopting the Immunic name. The company maintains operations in the United States and Germany, including corporate activities in Waltham, Massachusetts, and research and development operations in Germany. Its programs are investigational and remain subject to clinical testing and regulatory review.AI Generated. May Contain Errors. Read More Immunic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreIMUX MarketRank™: 2.631060307445 of 5 starsImmunic scored higher than 53% of companies evaluated by MarketBeat, and ranked 505th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingImmunic has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialImmunic has a consensus price target of $35.43, representing about 432.0% upside from its current price of $6.66.Amount of Analyst CoverageImmunic has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immunic's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Immunic are expected to grow in the coming year, from ($3.71) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immunic is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immunic is -1.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Immunic's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.10% of the float of Immunic has been sold short.Short Interest Ratio / Days to CoverImmunic has a short interest ratio ("days to cover") of 4.56.Change versus previous monthShort interest in Immunic has recently increased by 15.65%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmunic does not currently pay a dividend.Dividend GrowthImmunic does not have a long track record of dividend growth. News and Social Media2.1 / 5News Sentiment0.41 News SentimentImmunic has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Immunic this week, compared to 4 articles on an average week.Search InterestOnly 13 people have searched for IMUX on MarketBeat in the last 30 days. This is a decrease of -19% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Immunic to their MarketBeat watchlist in the last 30 days. This is a decrease of -13% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immunic insiders have not sold or bought any company stock.Percentage Held by Insiders5.49% of the stock of Immunic is held by insiders.Percentage Held by Institutions51.82% of the stock of Immunic is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immunic's insider trading history. Receive IMUX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMUX Stock News HeadlinesStifel Nicolaus Remains a Buy on Immunic (IMUX)October 10, 2026 | theglobeandmail.comImmunic (NASDAQ:IMUX) Stock Bumped Down to "Sell" by Wall Street ZenOctober 10, 2026 | americanbankingnews.comWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run, and Vertiv before a 1900 percent run. Now he's tracking a radical light-speed technology that could make AI 100 times faster and 100 times more energy efficient. Stocks tied to it have already climbed 133 percent, 217 percent, and 320 percent.October 14 at 1:00 AM | Brownstone Research (Ad)Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 the 10th Joint ACTRIMS-ECTRIMS MeetingOctober 8, 2026 | marketscreener.comMImmunic to present four vidofludimus calcium abstracts at MSToronto2026October 7, 2026 | proactiveinvestors.comImmunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS MeetingOctober 7, 2026 | prnewswire.comImmunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis TranscriptSeptember 11, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Immunic (IMUX) and UnitedHealth (UNH)September 11, 2026 | theglobeandmail.comSee More Headlines IMUX Stock Analysis - Frequently Asked Questions How have IMUX shares performed this year? Immunic's stock was trading at $5.3370 at the start of the year. Since then, IMUX shares have increased by 24.8% and is now trading at $6.66. How were Immunic's earnings last quarter? Immunic, Inc. (NASDAQ:IMUX) posted its quarterly earnings results on Tuesday, August, 11th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.36. When did Immunic's stock split? Shares of Immunic reverse split on Monday, April 27th 2026.The 1-10 reverse split was announced on Thursday, April 23rd 2026. The number of shares owned by shareholders was adjusted after the market closes on Sunday, April 26th 2026. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Immunic IPO? Immunic (IMUX) raised $63 million in an initial public offering on Thursday, April 17th 2014. The company issued 4,500,000 shares at a price of $13.00-$15.00 per share. How do I buy shares of Immunic? Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immunic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immunic investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Tesla (TSLA), Advanced Micro Devices (AMD), Palantir Technologies (PLTR), Plug Power (PLUG) and SoFi Technologies (SOFI). Company Calendar Last Earnings8/11/2026Today10/14/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 3 weeks, IMUX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:IMUX CIK1280776 Webwww.imux.com Phone(332) 255-9818Fax858-673-6843Employees95Year Founded2003Price Target and Rating Average Price Target for Immunic$35.43 High Price Target$70.00 Low Price Target$19.00 Potential Upside/Downside+432.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($4.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$97.17 million Net MarginsN/A Pretax MarginN/A Return on Equity-157.89% Return on Assets-107.88% Debt Debt-to-Equity RatioN/A Current Ratio5.05 Quick Ratio5.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.55) per share Price / Book-12.11Miscellaneous Outstanding Shares13,640,000Free Float12,895,000Market Cap$90.84 million OptionableOptionable Beta1.45 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:IMUX) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunic With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
